CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Share Options	Ordinary Shares	Non-voting Euro Deferred	Capital Redemption Reserve	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Additional Paid-in Capital Share Options	Accumulated Other Comprehensive Loss	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2020				56,171	4,000
Beginning balance at Dec. 31, 2020	$ 3,659,745			$ 6	$ 55	$ 472	$ 2,633,670			$ (134,352)	$ 1,159,894
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of ordinary shares in connection with the acquisition of GW Pharmaceuticals plc (in shares)				3,798
Issuance of ordinary shares arising from the acquisition of GW and share-based payment - pre-combination service	608,456		$ 3,555				608,456		$ 3,555
Issuance of ordinary shares in conjunction with exercise of share options (in shares)				1,042
Issuance of ordinary shares in conjunction with exercise of share options	119,058						119,058
Issuance of ordinary shares under employee stock purchase plan (in shares)				157
Issuance of ordinary shares under employee stock purchase plan	16,203						16,203
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)				465
Shares withheld for payment of employee's withholding tax liability	(35,602)						(35,602)
Share-based compensation	189,452						189,452
Other comprehensive (loss) income	(266,008)									(266,008)
Net (loss) income	(329,668)										(329,668)
Ending balance (in shares) at Dec. 31, 2021				61,633	4,000
Ending balance at Dec. 31, 2021	$ 3,965,191	$ (206,050)		$ 6	$ 55	472	3,534,792	$ (333,524)		(400,360)	830,226	$ 127,474
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Accounting standards update [Extensible Enumeration]	Accounting Standards Update 2020-06 [Member]
Issuance of ordinary shares in conjunction with exercise of share options (in shares)				832
Issuance of ordinary shares in conjunction with exercise of share options	$ 82,897						82,897
Issuance of ordinary shares under employee stock purchase plan (in shares)				139
Issuance of ordinary shares under employee stock purchase plan	15,123						15,123
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)				610
Shares withheld for payment of employee's withholding tax liability	(45,443)						(45,443)
Share-based compensation	223,279						223,279
Shares repurchased	(54)										(54)
Other comprehensive (loss) income	(725,149)									(725,149)
Net (loss) income	$ (224,060)										(224,060)
Ending balance (in shares) at Dec. 31, 2022	63,214			63,214	4,000
Ending balance at Dec. 31, 2022	$ 3,085,734			$ 6	$ 55	472	3,477,124			(1,125,509)	733,586
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of ordinary shares in conjunction with exercise of share options (in shares)	251			280
Issuance of ordinary shares in conjunction with exercise of share options	$ 30,189						30,189
Issuance of ordinary shares under employee stock purchase plan (in shares)				156
Issuance of ordinary shares under employee stock purchase plan	16,270						16,270
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)				735
Issuance of ordinary shares in conjunction with vesting of restricted stock units	0
Shares withheld for payment of employee's withholding tax liability	(50,952)						(50,952)
Share-based compensation	227,323						227,323
Shares repurchased (in shares)				(2,130)
Shares repurchased	(269,761)					1					(269,762)
Other comprehensive (loss) income	283,362									283,362
Net (loss) income	$ 414,832										414,832
Ending balance (in shares) at Dec. 31, 2023	62,255			62,255	4,000
Ending balance at Dec. 31, 2023	$ 3,736,997			$ 6	$ 55	$ 473	$ 3,699,954			$ (842,147)	$ 878,656